Dr. Niccola Funel | Rehabilitation | Excellence in Innovation
Lab Manager, Azienda Ospedaliera USL Nordovest; Department of Laboratory Diagnostics; Division of Immunohematology; Section of Laboratory Analysis, Italy
Dr. Niccola Funel is a distinguished molecular biologist and researcher specializing in clinical pathology, with a focus on personalized medicine. He holds two PhDs: one in Molecular and Experimental Oncology and the other in Translational Clinical Medicine. With over 250 scientific contributions, Dr. Funel is a prolific researcher and laboratory manager at Azienda Ospedaliera USL Nordovest in Italy. His expertise spans molecular biology, genetics, and epigenomics. He has also held advisory positions within the Italian Society of Pancreatology. Dr. Funel is a highly respected academic editor and reviewer for several international journals, contributing significantly to the medical and scientific communities. His work in the COVID-19 field since 2021 demonstrates his dedication to advancing medical research for practical, patient-centered outcomes.
Profile
Education
Dr. Niccola Funel’s academic journey has been marked by his commitment to advanced scientific research. He first completed his Bachelor’s in Molecular Biology, followed by specialization in Clinical Pathology. His pursuit of knowledge led him to earn two prestigious PhDs: the first in Molecular and Experimental Oncology and the second in Translational Clinical Medicine. This robust education foundation has equipped Dr. Funel with expertise in various molecular and clinical domains. His academic career has been further enriched through collaborations with renowned institutions, such as VU University (Amsterdam), Imperial College (London), and Karolinska Institute (Sweden). These educational experiences have allowed him to remain at the forefront of research in molecular biology, genetic expression, and epigenomics, reinforcing his significant contributions to the scientific and medical fields.
Experience
Dr. Niccola Funel’s extensive career spans roles as a molecular biologist, laboratory manager, and researcher. Since 2021, he has been serving as a biologist and research manager focused on COVID-19 research at Azienda Ospedaliera USL Nordovest in Italy. With over 250 published scientific contributions, he has made significant advancements in molecular biology and clinical applications, particularly in personalized medicine. Additionally, Dr. Funel has consulted for companies like Laica Microsystems and Menarini Diagnostics. His research collaborations span across leading universities such as VU University, Imperial College, and Karolinska Institute. Beyond research, Dr. Funel has held influential editorial roles, including academic editor, associate editor, and reviewer for top international journals. His experience has led to key patents and book publications, including Molecular Diagnostics and Treatment of Pancreatic Cancer, solidifying his reputation as a thought leader in molecular biology.
Research Focus
Dr. Niccola Funel’s primary research focus lies in molecular biology, genetic expression, and epigenomics, with particular emphasis on cancer biology and personalized medicine. He has dedicated much of his career to advancing the understanding of pancreatic cancer, seeking innovative diagnostic and therapeutic strategies. His research also explores the molecular mechanisms of tendinitis, where his work on the Polynucleotides High Purification Technology (PN HPT™) has garnered significant attention for improving treatment outcomes. Additionally, Dr. Funel is involved in exploring genetic determinants and epigenetic regulation in cancer, contributing to the emerging field of liquid biopsy for diagnosis, prognosis, and treatment monitoring. His extensive research collaborations with institutions such as the Karolinska Institute, Imperial College, and VU University have bolstered his position as a leader in molecular medicine, focusing on both basic science and translational clinical applications.
Publication Top Notes
- Polynucleotides High Purification Technology (PN HPTâ„¢) Injection Improves Pain Status and Functional Impairment in Hip and Shoulder Tendinitis
- Silver Nanoparticle-Coated Polyhydroxyalkanoate Based Electrospun Fibers for Wound Dressing Applications
- Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients
- Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets
- A Model of a Zebrafish Avatar for Co-Clinical Trials
- Triticum vulgare Extract Modulates Protein-Kinase B and Matrix Metalloproteinases 9 Protein Expression in BV-2 Cells: Bioactivity on Inflammatory Pathway Associated with Molecular Mechanism Wound Healing
- A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status
- Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line
- Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study
- Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment
- Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells
- Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
- The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer